Winship Cancer Institute/Emory University

Atlanta, Georgia 30388

40 studies enrolling now · 155 studies all time

What they study most

1st Line NSCLC, AFP Expressing Tumors, AML, Adult, Acute Graft-versus-host Disease, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Adenocarcinoma of the Prostate, Adenoid Cystic Carcinoma

Studies at this site

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Recruiting now
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma — Recruiting now
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis — Recruiting now
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) — Recruiting now
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma — Recruiting now
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis — Recruiting now
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) — Recruiting now
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma — Recruiting now
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — Recruiting now
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers — Recruiting now
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment — Recruiting now
L19IL2/TNF in Patients With Basal Cell Carcinoma — Recruiting now
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] — Recruiting now
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects — Recruiting now
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
A Study of PYX-201 in Advanced Solid Tumors — Recruiting now
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — Recruiting now
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia — Recruiting now
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) — Recruiting now
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors — Recruiting now
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Recruiting now
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas — Recruiting now
MAGIC Ruxolitinib for aGVHD — Recruiting now
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Recruiting now
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) — Recruiting now
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer — Recruiting now
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer — Recruiting now
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. — Recruiting now
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients — Recruiting now
Zopa Retreatment and Vector Shedding in Adults With RRP — Recruiting now
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL — Recruiting now
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma — Running, not enrolling
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Running, not enrolling
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors — Running, not enrolling
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase — Running, not enrolling